Related references
Note: Only part of the references are listed.Dynamic risk assessment to improve quality of care in patients with atrial fibrillation: the 7th AFNET/EHRA Consensus Conference
Larissa Fabritz et al.
EUROPACE (2021)
Clinical Potential of Targeting Fibroblast Growth Factor-23 and αKlotho in the Treatment of Uremic Cardiomyopathy
Jonathan P. Law et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2020)
Design and rationale of a pragmatic trial integrating routine screening for atrial fibrillation at primary care visits: The VITAL-AF trial
Jeffrey M. Ashburner et al.
AMERICAN HEART JOURNAL (2019)
Data-driven discovery and validation of circulating blood-based biomarkers associated with prevalent atrial fibrillation
Winnie Chua et al.
EUROPEAN HEART JOURNAL (2019)
Integrating new approaches to atrial fibrillation management: the 6th AFNET/EHRA Consensus Conference
Dipak Kotecha et al.
EUROPACE (2018)
N-Terminal Pro-B-Type Natriuretic Peptide in the Emergency Department The ICON-RELOADED Study
James L. Januzzi et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2018)
Lower soluble Klotho and higher fibroblast growth factor 23 serum levels are associated with episodes of atrial fibrillation
Katarzyna Mizia-Stec et al.
CYTOKINE (2018)
Stepwise mass screening for atrial fibrillation using N-terminal pro b-type natriuretic peptide: the STROKESTOP II study design
Johan Engdahl et al.
EUROPACE (2017)
Incidence of Previously Undiagnosed Atrial Fibrillation Using Insertable Cardiac Monitors in a High-Risk Population The REVEAL AF Study
James A. Reiffel et al.
JAMA CARDIOLOGY (2017)
FGF23/FGFR4-mediated left ventricular hypertrophy is reversible
Alexander Grabner et al.
SCIENTIFIC REPORTS (2017)
Screening for Atrial Fibrillation A Report of the AF-SCREEN International Collaboration
Ben Freedman et al.
CIRCULATION (2017)
Defining the major health modifiers causing atrial fibrillation: a roadmap to underpin personalized prevention and treatment
Larissa Fabritz et al.
NATURE REVIEWS CARDIOLOGY (2016)
A comparison of the CHARGE-AF and the CHA2DS2-VASc risk scores for prediction of atrial fibrillation in the Framingham Heart Study
Ingrid E. Christophersen et al.
AMERICAN HEART JOURNAL (2016)
Performance and Validation of a Novel Biomarker-Based Stroke Risk Score for Atrial Fibrillation
Jonas Oldgren et al.
CIRCULATION (2016)
2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
Piotr Ponikowski et al.
EUROPEAN HEART JOURNAL (2016)
2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS
Paulus Kirchhof et al.
EUROPEAN HEART JOURNAL (2016)
The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study
Ziad Hijazi et al.
LANCET (2016)
Association of Fibroblast Growth Factor 23 With Atrial Fibrillation in Chronic Kidney Disease, From the Chronic Renal Insufficiency Cohort Study
Rupal Mehta et al.
JAMA CARDIOLOGY (2016)
Activation of Cardiac Fibroblast Growth Factor Receptor 4 Causes Left Ventricular Hypertrophy
Alexander Grabner et al.
CELL METABOLISM (2015)
50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: a cohort study
Renate B. Schnabel et al.
LANCET (2015)
Fibroblast Growth Factor-23 and Incident Atrial Fibrillation The Multi-Ethnic Study of Atherosclerosis (MESA) and the Cardiovascular Health Study (CHS)
Jehu S. Mathew et al.
CIRCULATION (2014)
Fibroblast Growth Factor-23 and Incident Coronary Heart Disease, Heart Failure, and Cardiovascular Mortality: The Atherosclerosis Risk In Communities Study
Pamela L. Lutsey et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2014)
Simple Risk Model Predicts Incidence of Atrial Fibrillation in a Racially and Geographically Diverse Population: the CHARGE-AF Consortium
Alvaro Alonso et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2013)
Atrial Fibrillation Impairs the Diagnostic Performance of Cardiac Natriuretic Peptides in Dyspneic Patients Results From the BACH Study (Biomarkers in ACute Heart Failure)
Mark Richards et al.
JACC-HEART FAILURE (2013)
Fibroblast Growth Factor-23 and Death, Heart Failure, and Cardiovascular Events in Community-Living Individuals CHS (Cardiovascular Health Study)
Joachim H. Ix et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2012)
The phosphatonin fibroblast growth factor 23 links calcium–phosphate metabolism with left-ventricular dysfunction and atrial fibrillation
Sarah Seiler et al.
EUROPEAN HEART JOURNAL (2011)
FGF23 induces left ventricular hypertrophy
Christian Faul et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease
Tamara Isakova et al.
KIDNEY INTERNATIONAL (2011)
A New Equation to Estimate Glomerular Filtration Rate
Andrew S. Levey et al.
ANNALS OF INTERNAL MEDICINE (2009)
N-Terminal Pro-B-Type Natriuretic Peptide Is a Major Predictor of the Development of Atrial Fibrillation The Cardiovascular Health Study
Kristen K. Patton et al.
CIRCULATION (2009)
Prevention of Atrial Fibrillation Report From a National Heart, Lung, and Blood Institute Workshop
Emelia J. Benjamin et al.
CIRCULATION (2009)
Natriureettic peptides
Lori B. Daniels et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2007)
Expressing the modification of diet in renal disease study equation for estimating glomerular filtration rate with standardized serum creatinine values
Andrew S. Levey et al.
CLINICAL CHEMISTRY (2007)
Share Paper
